Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913459
rs121913459
ABL1
0.050 GeneticVariation BEFREE It suppressed primary Ph+ acute lymphatic leukemia-derived long-term cultures that either displayed nonmutational resistance or harbor the T315I. 25394714

2015
dbSNP: rs121913459
rs121913459
ABL1
0.050 GeneticVariation BEFREE The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. 22587422

2012
dbSNP: rs121913459
rs121913459
ABL1
0.050 GeneticVariation BEFREE This cell line may provide a useful model for in vitro and in vivo cellular and molecular studies of BCR-ABL-positive ALL with T315I mutation. 20471447

2010
dbSNP: rs121913459
rs121913459
ABL1
0.050 GeneticVariation BEFREE The objectives of this retrospective observational study were to estimate overall and progression-free survival for chronic myeloid leukemia in chronic-phase (CP), accelerated-phase (AP), or blastic-phase (BP) and Philadelphia chromosome-positive (Ph)(+) acute lymphoblastic leukemia (ALL) patients with T315I mutation. 19843886

2009
dbSNP: rs121913459
rs121913459
ABL1
0.050 GeneticVariation BEFREE Three patients with T315I abl-mutated chronic myeloid leukemia (CML) or Philadelphia chromosome (Ph)-positive acute lymphocytic leukemia (ALL) have achieved clinical responses to doses of MK-04547 that are not associated with adverse events. 16990603

2007